Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11932624 MDM2 degraders and uses thereof

Patent 11932624 was granted and assigned to Kymera Therapeutics on March, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Kymera Therapeutics

Current Assignee

Kymera Therapeutics

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

119326240

Patent Inventor Names

Nan Ji0

Xiaozhang Zheng0

Xiao Zhu0

Matthew M. Weiss0

Date of Patent

March 19, 2024

Patent Application Number

179630320

Date Filed

October 10, 2022

Patent Citations

‌

US Patent 7074620 Controlling protein levels in eucaryotic organisms

‌

US Patent 7083983 Inhibitors of the interaction between P53 and MDM2

‌

US Patent 7132421 CIS-imidazoles

‌

US Patent 7173015 Inhibition of Syk kinase expression

‌

US Patent 7208157 Proteolysis targeting chimeric pharmaceutical

‌

US Patent 6916833 Substituted piperidines

‌

US Patent 6949537 PI-3 kinase inhibitor prodrugs

‌

US Patent 7041298 Proteolysis targeting chimeric pharmaceutical

...

Patent Primary Examiner

CPC Code

Patent abstract

The present invention provides compounds, compositions thereof, and methods of using the same.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11932624 MDM2 degraders and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API